Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
October 13, 2017

Top indications for Australian clinical trials from 2012 – 2016

As part of our series of white papers tracking clinical trials activity around the world, GlobalData recently compiled a summary of clinical trial in Australia. GlobalData captured records of 3,199 clinical trials across all diseases and phases that had a start date January 01, 2012, and December 31, 2016.

The largest number of global clinical trials overall took place in non-small cell lung cancer, with 122 trials, followed by type 2 diabetes, hepatitis C, solid tumour, and breast cancer. Phase II was the most frequent phase across the major indications, as shown in Figure 1, ranging from 26–48% of trials for each indication. Phase III was the second most frequent phase, making up 54% of hepatitis C trials. Phase I made up the highest percentage in solid tumour trials.

Related Companies

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU